Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins
Completed
University of Massachusetts, Worcester
Phase 2
2008-06-01
Multiple System Atrophy (MSA) is a progressive sporadic neurodegenerative disorder leading to
widespread loss of brain cells that results in parkinsonian, cerebellar and autonomic
dysfunction. The cause of the MSA remains unclear. Available treatment is symptomatic only
and does not alter the course of disease.
Although the cause of MSA remains unclear, there is evidence of presence of common
neuroinflammatory mechanisms in the MSA brains including activation of microglia and
production of toxic cytokines. This research protocol is based on hypothesis that the MSA
progression can be altered by blocking the neuroinflammatory activity.
This protocol includes administration of intravenous immunoglobulin (IVIg). IVIg contains
antibodies derived from human plasma which can block the inflammatory responses in the brain
that can lead to loss of brain cells.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
